Literature DB >> 18573290

Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.

Kaifan Dai1, Ying Liu, Mingjie Liu, Jianqing Xu, Wei Huang, Xianggang Huang, Lianxing Liu, Yanmin Wan, Yanling Hao, Yiming Shao.   

Abstract

Interest is increasing regarding replicating poxvirus as HIV vaccine vector. In China, the Tiantan Vaccinia Virus (TV) has been used most extensively in the battle of eradicating smallpox. Recently, TV was developing as vaccine vector to fight against infectious diseases such as human immunodeficiency virus (HIV). However, replicating vaccinia virus sometimes may pose serious post-vaccination complications, especially in immunosuppressed individuals. To develop a safer and more effective TV-based vector, we constructed C12L (vIL-18 binding protein) and A53R (vTNF receptor homolog) gene-deleted mutants which are based on parental TV and VTKgpe (TV expressing HIV gagpol and env gene), respectively. The pathogenicity and immunogenicity were also evaluated. Deleting these two immunomodulatory genes lessened the virulence of the parental virus in both mice and rabbit models. Notably, C12L deletion mutant attenuated the skin virulence of parental virus by as high as approximate 2 logs. Furthermore, VTKgpe with A53R and C12L gene deletion retains the high immunogenicity of the parental virus to elicit strong humoral and cellular responses to the HIV target genes despite the remarkable attenuation. These data suggest that deletion of the cytokine viroceptor gene is feasible to obtain a safer and replication-competent TV vector for vaccination and immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573290     DOI: 10.1016/j.vaccine.2008.06.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Nirmal Ganguly; Linqi Zhang; Hiko Tamashiro; David A Cooper; Mean Chhi Vun; Budiman Bela; Rossana Ditangco; Nguyen Van Kinh; Alan Bernstein; Saladin Osmanov; Bonnie Mathieson; Stephen J Kent; Yiming Shao
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 2.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

Review 3.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques.

Authors:  Margherita Rosati; Candido Alicea; Viraj Kulkarni; Konstantin Virnik; Max Hockenbury; Niranjan Y Sardesai; George N Pavlakis; Antonio Valentin; Ira Berkower; Barbara K Felber
Journal:  Vaccine       Date:  2015-03-21       Impact factor: 3.641

5.  HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

Authors:  Juan García-Arriaza; Beatriz Perdiguero; Jonathan L Heeney; Michael S Seaman; David C Montefiori; Nicole L Yates; Georgia D Tomaras; Guido Ferrari; Kathryn E Foulds; Mario Roederer; Steven G Self; Bhavesh Borate; Raphael Gottardo; Sanjay Phogat; Jim Tartaglia; Susan W Barnett; Brian Burke; Anthony D Cristillo; Deborah E Weiss; Carter Lee; Karen V Kibler; Bertram L Jacobs; Ralf Wagner; Song Ding; Giuseppe Pantaleo; Mariano Esteban
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 6.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

7.  Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Authors:  José Luis Nájera; Carmen Elena Gómez; Juan García-Arriaza; Carlos Oscar Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

8.  Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Authors:  Lucas Sánchez-Sampedro; Carmen Elena Gómez; Ernesto Mejías-Pérez; Eva Pérez-Jiménez; Juan Carlos Oliveros; Mariano Esteban
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

Review 9.  Development of replication-competent viral vectors for HIV vaccine delivery.

Authors:  Christopher L Parks; Louis J Picker; C Richter King
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

10.  Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.

Authors:  Lianxing Liu; Yanling Hao; Zhenwu Luo; Yang Huang; Xintao Hu; Ying Liu; Yiming Shao
Journal:  Vaccine       Date:  2012-05-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.